Clinical Trial Update: A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder [Phase 2]

View source ↗

Summary

Phase 2 study of CLE-100, an oral esketamine, as an adjunct to standard antidepressants for major depressive disorder, has completed its trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• CLE-100 (oral esketamine) (esketamine)

Snippet

Sponsor: Clexio Biosciences Ltd. | Conditions: Adjunctive Treatment of Major Depressive Disorder (MDD) | Phase 2 | Status: COMPLETED